A radioimmunoassay for prostaglandin E 2 (PGE 2) in urine was developed and validated. It was used to provide serial measurements in eight renal transplant patients. Urine PGE 2 concentration was increased between 1 and 7 days before any changes in the conventional biochemical indicators of acute rejection, serum creatinine and creatinine clearance. The increases in PGE 2 concentration varied from 3 to 50 times that of the previous day. These results suggest that measurement of urinary PGE 2 may be useful as an early indicator of acute renal transplant rejection.
Acute rejection of the donor kidney is the most important cause of renal transplant failure. Such episodes are treated either with i.v. doses of 0·5 g or 1·0 g prednisolone or a 10 to 14 day course of high-dose oral ster~id therapy. In view of the serious side effects of high doses of steroids, they should only be given when there is good evidence of rejection. There is therefore a need for accurate markers of rejection to increase the certainty of diagnosis and early diagnosis of rejection might allow smaller steroid doses to be administered although there is no conclusive evidence of this.
Examples of such potential markers are N-acetyl-~-D-glucosaminidase, 1~2-microglo bulin,2 lysozyme.:' and retinol binding protein" in urine, or fibrin degradation products" in serum as well as the more routinely available tests such as serum creatinine and creatinine clearance. These 'routine' tests are relatively insensitive and show changes only when the rejection is established. They are however, technically simple and rapid to perform. The other tests listed have yet to be proven to be more useful": 7 and may incur significant penalties in terms of analytical speed, simplicity and robustness.
Renal ischaemia is one of the early consequences of the rejection reaction'' and this is ' accompanied by an increase in renal prostaglandin production." We therefore decided to measure urine PGE 2 excretion in renal transplant patients and to evaluate its usefulness as an early marker of acute rejection.
Methods

SUBJECTS
Consecutive 24 hour specimens of urine were collected from all patients into plastic containers containing thymol crystals as soon as the transplanted kidney had started to function. Urine volumes were recorded and an aliquot was analysed for protein and creatinine concentration. A 25 mL aliquot of each collection was stored at -20°C and if that patient had suffered a rejection episode in the first 6 weeks after the transplanted kidney had started to function, it was analysed retrospectively for PGE 2. The criterion of rejection was a rise in serum creatinine of a degree which was considered to justify clinically the i.v. administration of prednisolone.
Of the eight patients seven were male and one was female. Seven received cadaveric transplants whilst one kidney was from a live donor.
MATERIALS
All reagents used were A.R. grade. Solvents were obtained from British Drug Houses Ltd, Poole, Dorset, England. Sephadex LH20 was obtained from Pharmacia Ltd, Hounslow, Middlesex, England. Tritiated PGE 2 ([5, 6, 8, 11, 12, 14, 15 (n)-JH] prostaglandin E 2) was obtained from Amersham International PLC, Amersham, England (the chemical had a quoted deterioration of less than 4% per month at -20°C). Pure prostaglandin E 2 and freezedried antiserum to PGE 2 was obtained from Sigma (London) Chemical Co. Ltd, Poole, Dorset, England. The antiserum was reconstituted in 11 mL of 0·1 rnol/L phosphate buffered saline, pH 7·4, and was stable for at least 30 days at 4°C.
Dilutions of stock solutions are made throughout in 'phosphate buffered saline', 0·1 mol/L phosphate, pH 7-4 in deionised water containing 155 mmol/L sodium chloride, 0·1 % gelatin and 0·1% sodium azide.
METHOD FOR PGE2 ANALYSIS
(a) Extraction procedure A 25 mL aliquot of urine was adjusted to pH 4·5 with 1 mmol/L HC!. To 20 mL of this sample was added 0·01 IiCi eH]PGE 2 [specific activity: 438 mCi/mg (16·2 GBq/mg)] and duplicate 5 mL aliquots were extracted with 15 mL ethyl acetate by vortex mixing for 30 s. Ten millilitres of each ethyl acetate extract were dried down under nitrogen at 40°C, redissolved in 200 IiL eluting solvent (dichloromethane! methanol, 98/2 vol/vol, acidified by the addition of 0·5 vol of glacial acetic acid). This solution was then applied (with a 200 IiL rinse), to the top of a Sephadex LH20 column (llxO·5 em) and eluted at approximately 2 mUmin. Routinely, six urine samples could be conveniently processed in duplicate as a batch. The 9 to 19 mL eluate fraction for each sample was collected, dried down under nitrogen at 40°C and was redissolved in 300 IiL ethanol/water (70:30 vol/vol). A 50 IiL aliquot was diluted to 1·25 mL with phosphate buffered saline for radioimmunoassay and a further 150 IiL aliquot was taken for liquid scintillation counting for the estimation of recovery of added tracer. The mean recovery of added tracer (±SD) was 59·4±6·3%.
(b) Radioimmunoassay
Standard solutions of PGE 2 were prepared in buffer with concentrations of 1~100 nglL (0·1-10 pgltube). Standard, diluted urine extract or phosphate buffered saline as blank (100 IiL) was added to polypropylene tubes (Sarstedt Ltd, 55 x 12 rnrn) followed by 100 IiL of a solution containing 0·5 IiCi eH]PGE 2 per ml in phosphate buffered saline. Two volumes of antibody solution were diluted with three volumes of phosphate buffered saline and 100
IiL aliquots of diluted antibody were added to all tubes except the non-specific binding tubes and left for 10 min at room temperature. The tubes were then placed in an ice bath and left for 2 h. After this period 1 mL of ice-cold dextran coated charcoal (0·25%, Norit A, 0·025% Dextran TID in phosphate buffered saline) was added to each tube as rapidly as possible. After immediate vortex mixing the tubes were left for 10 min before centrifugation at 1500 g and 4°C for 10 min. One mL of the supernatant was transferred to 10 mL of scintillation fluid (Scintillator 99, Packard Instrument Ltd, Berks, England) and counted on a Packard Tri-Carb Model 3330 scintillation counter. Each tube was counted twice for 5 min and the counts were averaged. A plot was made of standard concentration versus B x !B", (ratio of counts in the sample tube to those in the zero standard tube) and results for each test sample were interpolated from the standard curve. Measured concentrations of PGE 2 were corrected for recovery of tracer during the extraction procedure.
Measurements of serum and urine creatinine, creatinine clearance and urine protein were performed by routine methods in an patients.
Results
VALIDATION OF ASSAY (i) Specificity
Using the radioactively labelled compounds, prostaglandins A and B eluted separately while 50% of PGE I was found in the 'PGE 2 ' fraction eluted from the Sephadex LH20 column. The manufacturer's stated cross-reactivity of the antibody for PGE I was 3·2% for B xl8,,=0·5. In our hands it was found to be 9·5%. However PGE I is not synthesised by the kidney!" and plasma PGE I is metabolised before being excreted in the urine. II We have therefore assumed no significant contamination by PGE 1 in this assay. (ii) Sensitivity The sensitivity of the assay (defined as the amount of PGE 2 causing a 10% reduction of counts from the reading of the zero standardj'j was 2·8 pg/tube.
(iii) Precision
Within-and between-batch precision figures are shown in Table 1 . Within-batch precision was calculated from the duplicate analysis of each sample. Between-batch precision was calculated from repeat analysis of a pooled urine sample stored at -20°C. There was no apparent deterioration in the pool over 6 months.
(iv] Recovery Recovery was determined, as an indicator of accuracy, by the analysis in ten separate assays of two urines containing added PGE 2 concentrations of 100 and 500 ng/L, The results are shown in Table 2 .
As further evidence that the assay was measuring prostanoids, urine PGE 2 was measured in six normal male volunteers before and after they had taken indomethacin (a Urine PGE 2 was measured in eight patients who had suffered episodes of acute renal transplant rejection and was compared with routine measurements of serum creatinine, and creatinine clearance. The PGE 2 data is summarised in Table 3 . Figure 1 shows these changes in one of the patients. In seven of the eight patients an increase in urine PGE 2 excretion preceded an increase in serum creatinine or a decrease in creatinine clearance by 1-7 days (mean: 3·1±0·8 days). In the eighth case PGE 2 excretion showed several marked increases preventing interpretation of the data. In the seven cases where a rise in urine PGE 2 preceded the rejection episode the peak increases were between 3 and 50 times the level of the previous day. The magnitude of the peak varied between 190 and 5500 ngl24 h and did not appear to be related to the severity or outcome of the rejection episode. The urinary concentration of PGE 2 during rhe episodes of rejection varied between 50 and 1700 ngl24 h and was generally less than 100 ngl24 h when renal function was stable. These concentrations appear lower than those measured in eight healthy hospital staff, in whom the mean PGE 2 excretion (±SD) was 660±147 ngl24 h [range 'This is the low value found immediately before the PGE, peak after retrospective analysis. tData from ease 2 not included in calculation-see discussion. tLead time is the time by which the peak of PGE, excretion preceded the clinical diagnosis of rejection. (mean±2 SD)=366-954 ng/24 h.] These results in normal subjects are in agreement with published data'" and are significantly higher than the results in the transplant patients (t-test=4'50; P<O·OOl).
Discussion
We have established and validated an assay for PGE z in urine and used it to test the hypothesis that the ischaemia of renal transplant rejection would lead to the increased excretion of this vasodilatory compound. The assay was shown to be satisfactory in terms of specificity, sensitivity, recovery and precision and when used to monitor acute rejection episodes, indicated that increases in urine PGE z can precede changes in serum creatinine and creatinine clearance by 1 to 7 days in seven of the eight patients studied and predicted impending rejection. In the eighth patient interpretation of urine PGE z excretion at the time of rejection was impossible because of several high peaks during the preceding weeks. The reason for this is not known but may have resulted from seminal fluid contamination of the urine. Urine~-N-acetyl-glucosaminidase (NAG) has been reported to be increased for 1-5 days prior to the clinical diagnosis in 70% of renal transplant rejection episodes." Whilst urine NAG measurement is simple and inexpensive, increased activity can be found in many conditions other than acute rejection so that these other causes must be excluded before treatment can be initiated. The same argument applies to measurement of serum and urine~2" microglobulin in that both give a high number of false positive and false negative results. 15 Other workers!" have shown that the urine excretion of another prostanoid, thromboxane B z (TXB z ) was increased prior to a rise of serum creatinine in 26 of 30 rejection episodes. This assay suffers from the disadvantage that there may be a release of TXB z from non-renal cellular components and this may give rise to false positive from non-renal pathologies, e.g. deep vein thrombosis.
Our assay should in theory be a highly sensitive method in the diagnosis of acute rejection episodes, since urinary PGE z excretion rates are very stable in patients on a normal dietary sodium intake, in the absence of diuretic therapy. I? The sensitivity of the assay is seen in Fig. 1 where an inflexion in the serum creatinine before the diagnosed acute rejection episode coincided with an increased excretion of PGE z. This could mean that the assay is too sensitive in that this increase in PGE z excretion could have led to a false diagnosis of acute rejection, when in fact no treatment was necessary. Similar small increases in PGE 2 excretion were observed in a number of patients who showed temporary inflexions in serum creatinine.
The increase in urine PGE 2 excretion prior to the rejection was transient, falling back to baseline levels within 2-3 days with the peak increase varying between 3 and 50 times the excretion of the previous day. This is in sharp contrast to the slow changes in serum creatinine concentrations. It thus appears that urine PGE 2 excretion rates are not of value in following the progress of a rejection episode.
Other than during periods of rejection, the urine PGE 2 excretion in the patients was much lower than that found in normal individuals. This may reflect one aspect of kidney function which has not yet returned to normal after transplantation.
The present assay has the disadvantages that although the radioimmunoassay step takes only 3 h, the extraction and chromatographic stages require approximately 6 h. Also, the labourintensive nature of the assay means that only six urine samples can comfortably be processed in one batch. Thus the results of an assay cannot be made available until the day after the urine collection has been completed. Since the assay would be of greater value if the results were available the same day, we are developing an automated method for the initial extraction and chromatographic stages.
In conclusion, advance warning of rejection enables one to observe the patient more closely over the next few days and also early treatment may lead to a higher success rate in reversing the rejection process (although this has not been proven). In this study we have described a sensitive and reliable assay for measurement of urinary PGE 2 and shown that it is an early indicator of acute renal transplant rejection.
